The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595
Scientific title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of OP0595 Administered Intravenously in Healthy Male Subjects.
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers 0 0
Bacterial Infections 0 0
Condition category
Condition code

Study type
Description of intervention(s) / exposure
Treatment: Drugs - OP0595
Treatment: Drugs - Placebo

Experimental: Ascending single dose of OP0595 -

Placebo Comparator: Normal Saline -

Treatment: Drugs: OP0595
Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

Treatment: Drugs: Placebo
Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Safety from baseline through the end of the study - Number of patients with adverse events
Timepoint [1] 0 0
Day 1 to Day 7
Secondary outcome [1] 0 0
Plasma PK parameters of OP0595 and its metabolites - Cmax, tmax, AUC0-last, AUC0-inf, Kel, T1/2, CLtot, Vdss
Timepoint [1] 0 0
Day 1 to Day 2
Secondary outcome [2] 0 0
Urine PK parameters of OP0595 and its metabolites - Ae, Ae0-t, Ae0-t/Dose, CLr
Timepoint [2] 0 0
Day 1 to Day 2

Key inclusion criteria
- Caucasian males aged between 18 and 45 years (inclusive) at Screening

- A Body Mass Index (BMI) between 18.0 and 30.0 kg/m² (inclusive) at Screening

- Good general health as determined by the Investigator based on medical history,
physical examination, vital signs, 12-lead ECG and clinical laboratory tests

- Negative urine test for drugs of abuse and breath test for alcohol both at Screening
and Day -1
Minimum age
18 Years
Maximum age
45 Years
Can healthy volunteers participate?
Key exclusion criteria
- Receipt of any investigational agent or drug within four months before Screening

- A history or current evidence of allergic symptoms such as bronchial asthma,
drug-induced rash or urticaria

- Hypersensitivity and/or allergy to drugs

- Concurrent or history of clinically significant cardiovascular, hepatic, renal,
endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or hematological

- A history of chronic or recurrent infections or current active infection

- A recent history of surgery within three months prior to Screening, determined by the
Investigator to be clinically relevant

- A history or presence of malignancy

- Donation of blood (or loss of blood) greater than 400 ml within three months before

- A history of smoking at any time within one year before Screening

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people analysing the results/data
Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Perth,
Recruitment postcode(s) [1] 0 0
- Perth,

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Meiji Seika Pharma Co., Ltd.

Ethics approval
Ethics application status

Brief summary
The objectives of this study are to assess the safety, tolerability and pharmacokinetic
profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at
single escalating doses.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Mitsuharu Egawa
Address 0 0
Meiji Seika Pharma Co., Ltd.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications